Unreliable Observations from a Confounded Analysis of a Skewed Database - 26/07/17

Doi : 10.1016/j.amjmed.2017.03.003

Philippe Gabriel Steg, MD ^a,^b, Robert A. Harrington, MD ^c, Anders Himmelmann, MD, PhD ^d, Stefan K. James, MD, PhD ^e, Karen S. Pieper, MS ^f, Lars Wallentin, MD, PhD ^e
^a Hôpital Bichat, Assistance Publique-Hôpitaux de Paris, Université Paris Diderot, France
^b Institut National de la Santé et e la Recherche Médicale U1148 Laboratory for Vascular Translational Science, Paris, France
^c Department of Medicine, Stanford University, Calif
^d AstraZeneca Research and Development, Gothenburg, Sweden
^e Department of Medical Sciences, Cardiology and Uppsala Clinical Research Center, Uppsala University, Sweden
^f Duke Clinical Research Institute, Duke University Medical Center, Durham, NC

Le texte complet de cet article est disponible en PDF.

	Funding: None.
	Conflict of Interest: PGS discloses the following relationships: research grant from Merck, Sanofi, and Servier; speaking or consulting fees from Amarin, Amgen, AstraZeneca, Bayer, Boehringer-Ingelheim, Bristol-Myers-Squibb, CSL-Behring, Daiichi-Sankyo, GlaxoSmithKline, Janssen, Lilly, Merck Novartis, Pfizer, Regeneron, Sanofi, Servier, The Medicines Company. RAH discloses the following relationships: Consultant fees/honoraria from Adverse Events, Amgen Inc., Gilead Sciences, Inc., Merck, The Medicines Company, Vida Health, and WebMD; data safety monitoring board member for AstraZeneca, Bristol-Myers Squibb, and Janssen RnD; research grants from CSL Behring, Novartis Corporations, Portola, Sanofi-Aventis, and The Medicines Company; ownership interest in Element Science, and MyoKardia; Director of Signal Path (Evidint), Scanadu, American Heart Association, and Stanford Healthcare. AH is an employee of AstraZeneca. SKJ discloses the following relationships: institutional research grant, honoraria and consultant/advisory board fee from AstraZeneca; institutional research grant and consultant/advisory board fee from Medtronic; institutional research grants and honoraria from The Medicines Company; consultant/advisory board fees from Janssen, Bayer. KSP discloses the following relationships: institutional grant from AstraZeneca and Bayer. LW discloses the following relationships: institutional research grants, consultancy fees, lecture fees, and travel support from Bristol-Myers Squibb/Pfizer, AstraZeneca, GlaxoSmithKline, Boehringer Ingelheim; institutional research grants from Merck & Co, Roche; consultancy fees from Abbott.
	Authorship: All authors had a role in writing the manuscript.